過敏性:世界の治験レビュー(2017年下半期版)

【英語タイトル】Hypersensitivity Global Clinical Trials Review, H2, 2017

GlobalDataが出版した調査資料(GDHC4621CTIDB)・商品コード:GDHC4621CTIDB
・発行会社(調査会社):GlobalData
・発行日:2017年10月31日
・ページ数:536
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD7,500 ⇒換算¥847,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における過敏性治療の臨床試験動向について調査・分析し、アジア/ヨーロッパ/アメリカ/中南米の主要国における治験件数、フェーズ別の治験件数、進捗状況別の治験件数、有望なスポンサー、有望な薬剤、治験関連の最新ニュース、主要企業分析、主要な治験プロファイル分析などの情報をご提供致します。
・過敏性:主要地域別治験動向
・過敏性:アジア市場
・過敏性:ヨーロッパ市場
・過敏性:アメリカ市場
・過敏性:中南米市場
・過敏性:中東・アフリカ市場
・過敏性:段階(フェーズ)別治験件数
・過敏性:進捗状況別の治験件数
・過敏性:スポンサーの種類別治験件数
・過敏性:有望なスポンサー
・過敏性:有望な薬剤分析
・過敏性:主要企業分析
【レポートの概要】

Hypersensitivity Global Clinical Trials Review, H2, 2017

Summary

GlobalData’s clinical trial report, “Hypersensitivity Global Clinical Trials Review, H2, 2017″ provides an overview of Hypersensitivity clinical trials scenario. This report provides top line data relating to the clinical trials on Hypersensitivity. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Hypersensitivity to Immunology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Hypersensitivity to Immunology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 26
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Hypersensitivity Therapeutics Clinical Trials 31
Prominent Drugs 33
Clinical Trial Profile Snapshots 34
Appendix 534
Abbreviations 534
Definitions 534
Research Methodology 535
Secondary Research 535
About GlobalData 536
Contact Us 536
Source 536

List of Tables
Hypersensitivity Therapeutics, Global, Clinical Trials by Region, 2017* 7
Hypersensitivity Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Hypersensitivity Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Hypersensitivity Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
Hypersensitivity Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
Hypersensitivity Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
Hypersensitivity Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 14
Hypersensitivity Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 15
Proportion of Hypersensitivity to Immunology Clinical Trials, G7 Countries (%), 2017* 16
Hypersensitivity Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Hypersensitivity Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Hypersensitivity to Immunology Clinical Trials, E7 Countries (%), 2017* 19
Hypersensitivity Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
Hypersensitivity Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
Hypersensitivity Therapeutics, Global, Clinical Trials by Phase, 2017* 22
Hypersensitivity Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
Hypersensitivity Therapeutics, Global, Clinical Trials by Trial Status, 2017* 25
Hypersensitivity Therapeutics Clinical Trials, Global, by End Point Status, 2017* 26
Hypersensitivity Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 27
Hypersensitivity Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 28
Hypersensitivity Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30
Hypersensitivity Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 32
Hypersensitivity Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 33

List of Figures
Hypersensitivity Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Hypersensitivity Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Hypersensitivity Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Hypersensitivity Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
Hypersensitivity Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
Hypersensitivity Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
Hypersensitivity Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 14
Hypersensitivity Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 15
Proportion of Hypersensitivity to Immunology Clinical Trials, G7 Countries (%), 2017* 16
Hypersensitivity Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
Hypersensitivity Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
Proportion of Hypersensitivity to Immunology Clinical Trials, E7 Countries (%), 2017* 19
Hypersensitivity Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
Hypersensitivity Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
Hypersensitivity Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
Hypersensitivity Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
Hypersensitivity Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
Hypersensitivity Therapeutics Clinical Trials, Global, by End Point Status, 2017* 26
Hypersensitivity Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 27
Hypersensitivity Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 28
Hypersensitivity Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29
Hypersensitivity Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
Hypersensitivity Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 33
GlobalData Methodology 535

【掲載企業】

The Lundbeck Foundation
Circassia Pharmaceuticals Plc
Stallergenes Greer plc
GlaxoSmithKline Plc
Allergy Therapeutics Plc
Novartis AG
Merck & Co Inc
Droege International Group AG
DBV Technologies SA
Aimmune Therapeutics Inc

【レポートのキーワード】

過敏性、治験、臨床試験、治療薬

★調査レポート[過敏性:世界の治験レビュー(2017年下半期版)] (コード:GDHC4621CTIDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[過敏性:世界の治験レビュー(2017年下半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆